Terms ending in 2043
Every in-force patent on Pharma Cinq, LLC's record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,577,270 | 2',3'-Diacetyluridine Substituted With Acetoacetyl at the 5' Position In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 12,649,739 | Imidazoquinoline Compound Having Anti-Inflammatory, Antifugal, Antiparasitic, and Anticancer Activity In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 12,703,718 | Compositions and Compounds for Co-Delivery of Uridine and Ketoleucine In force · High confidence | Pharma Cinq, LLC | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.